PROCEPT BioRobotics
PROCEPT BioRobotics (PRCT) develops and commercialises a minimally invasive robotic system for treating benign prostatic hyperplasia (BPH). Its flagship Aquablation therapy uses a precision waterjet and real-time imaging to remove prostate tissue, positioning the company in the specialised urology devices niche. Investors should know the business model leans on system sales plus recurring consumable and service revenue as clinical adoption grows. Growth drivers include expanding procedure volumes, broader clinical evidence, international regulatory approvals and increased installed base. Key risks are adoption hurdles versus established surgical approaches and drugs, reimbursement pressures, execution on commercial expansion, and the possibility of variable procedure volumes. As a smaller-cap medical device company (market cap roughly $1.9bn), PRCT can be more volatile than large healthcare names and may need ongoing investment to scale. This is general educational information — not personalised investment advice — and potential investors should consider how such a stock fits their risk tolerance and portfolio goals.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying PROCEPT BioRobotics stock with a target price of $53.73, indicating growth potential.
Financial Health
PROCEPT BioRobotics is performing well with strong revenue and profit margins, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PRCT
Rise Of The Machines: The Robotics Revolution
This basket focuses on companies at the forefront of the robotics and automation revolution. It provides exposure to both the hardware manufacturers and the software developers driving this technological shift.
Published: August 12, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Installed Base Growth
Increasing system installations can lift recurring consumable and service revenue, though adoption rates may vary by region and clinic.
International Expansion
Broader regulatory approvals and market entries could open sizeable new markets, but execution and local reimbursement remain key challenges.
Clinical Evidence Momentum
Stronger trial data can support clinician confidence and referrals, though study outcomes and long-term adoption can be uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
